BRVE
Braveheart Bio reports Q2 2026 financial results
Company announced $122.8M cash balance and advanced Phase 3 LIONHEART-HCM trial for cardiac drug BHB-1893.
BRVE news
Latest 2 stories · newest Sep 8, 2026
BRVE
Braveheart files amended charter authorizing additional common stock
Braveheart Bio filed its second amended and restated certificate of incorporation, increasing its authorized common stock to 500 million shares and eliminating existing preferred stock designs. Filings are typically driven by capital structure changes needed for future corporate moves.
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same BRVE feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/BRVE/newsSTART FREE